Market Research Logo

NPS+ (EU5) [HIV]

NPS+ (EU5) [HIV]

Introduction

Doctors upbeat about HIV treatments, but satisfaction runs highest for 2 brands

Doctors may be satisfied with available HIV treatments overall, but when we surveyed 150 EU5-based infectious disease specialists and general practitioners, four of the nine brands we asked them about earned negative satisfaction scores. Meanwhile, the top two brands are way ahead, and both are poised for big market share gains

Find out how your brand measures up, and what you can do to boost your score in FirstView’s NPS+ HIV 2017 (EU5).

Building on the respected net promoter score (NPS), the report compares loyalty for nine major HIV drugs. Easy-to-use KPIs highlight ways you can improve brand health, while a unique “Brand DNA” section—packed with candid comments from doctors—may reveal what’s keeping leading brands on top, and holding lagging brands back.

Reasons to Purchase

Top Takeaways

Doctors are upbeat: More than half of the surveyed brands earned positive net promoter scores (NPSs), and nearly three quarters of doctors surveyed are satisfied with available brands.

Two brands lead the pack: the top two brands score nearly four and five times as high as their third-place rival respectively.

Brand DNA shows that some brands are on the way out: Several of the surveyed brands are outdated, have better alternatives, or face declining use, according to some detractors.

Three brands are poised for big gains: The top two brands and the eighth-place brand each stand to increase their market share by 400 percent or more if they can win over Detractors.

The last-place brand is in big trouble: Nearly half of surveyed doctors are Detractors, and brand attribute analysis shows that few messages resonate with more than ten percent of Promoters.

Doctors use whatever works: Loyalty scores are low and Promoters of one brand tend to promote nearly four others on average. Cost is not a strong driver of recommendations.

Insight into 10 Major HIV Brands

Descovy (emtricitabine/tenofovir alafenamide; Gilead)

Genvoya (cobicistat/elvitegravir/emtricitabine/ tenofovir alafenamide; Gilead)

Isentress (raltegravir; Merck & Sharpe & Dohme.)

Prezista (darunavir; Janssen Cilag)

Reyataz (atazanavir; BMS)

Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead)

Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)

Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)

Viread (tenofovir disoproxil fumarate; Gilead)

A Report Based on Expert Knowledge

We surveyed 150 infectious disease specialists and general practitioners from the EU5 countries (France, Italy, Germany, Spain, UK), chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.We conducted the survey between February 3rd and 8th, 2017.

Explore Important Brand Loyalty Issues

NPS+ HIV 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn:

How satisfied doctors are with HIV treatments

How loyal doctors are to your brand.

How many other brands your Promoters recommend.

Which other brands your Promoters and Detractors recommend.

How much market share your brand has among Promoters and Detractors.

How much market share you stand to gain by converting Detractors into Promoters.

.Which messages Promoters, Passives and Detractors associate with your brand.

Your brand DNA: what doctors really think of your brand—in their own words.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

How likely are you to recommend this brand to a colleague?



Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.

Passives are those who answer 7 – 8.

Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter).

The higher the score the healthier the brand.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


1.Chart 1: Net Promoter Score?
2.Chart 2: How loyal are doctors to my brand?
3.Chart 3: How satisfied is the market?
4.Chart 4: How many other brands are promoted by my Promoters?
5.Chart 5: Which other brand is most promoted by my Promoters?
6.Chart 6: Which other brands are promoted by my Detractors?
7.Chart 7: What is my brand's market share among Promoters and Detractors?
8.Chart 8: What brand messages are associated with Promoters, Passives and Detractors (by brand)?
9.Chart 9: What does my brand represent to Promoters and Detractors (by brand)?
10.Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report